Phthalazine Derivatives as Parp Inhibitors

ABSTRACT

The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R 1 , R 2  L 1 , L 2 , X, Y, Q and Z have defined meanings.

FIELD OF THE INVENTION

The present invention relates to inhibitors of PARP and provides compounds and compositions containing the disclosed compounds. Moreover, the present invention provides methods of using the disclosed PARP inhibitors for instance as a medicine.

BACKGROUND OF THE INVENTION

The nuclear enzyme poly(ADP-ribose)polymerase-1 (PARP-1) is a member of the PARP enzyme family. This growing family of enzymes consist of PARPs such as, for example: PARP-1, PARP-2, PARP-3 and Vault-PARP; and Tankyrases (TANKs), such as, for example: TANK-1, TANK-2 and TANK-3. PARP is also referred to as poly(adenosine 5′-diphospho-ribose) polymerase or PARS (poly(ADP-ribose) synthetase).

PARP-1 is a major nuclear protein of 116 kDa consisting of three domains: the N-terminal DNA binding domain containing two zinc fingers, the automodification domain and the C-terminal catalytic domain. It is present in almost all eukaryotes. The enzyme synthesizes poly(ADP-ribose), a branched polymer that can consist of over 200 ADP-ribose units. The protein acceptors of poly(ADP-ribose) are directly or indirectly involved in maintaining DNA integrity. They include histones, topoisomerases, DNA and RNA polymerases, DNA ligases, and Ca²⁺- and Mg²⁺-dependent endonucleases. PARP protein is expressed at a high level in many tissues, most notably in the immune system, heart, brain and germ-line cells. Under normal physiological conditions, there is minimal PARP activity. However, DNA damage causes an immediate activation of PARP by up to 500-fold.

Tankyrases (TANKs) were identified as components of the human telemeric complex. They have also been proposed to have a role in vesicle trafficking and may serve as scaffolds for proteins involved in various other cellular processes. Telomeres, which are essential for chromosome maintenance and stability, are maintained by telomerase, a specialized reverse transcriptase. TANKs are (ADP-ribose)transferases with some features of both signalling and cytoskeletal proteins. They contain the PARP domain, which catalyses poly-ADP-ribosylation of substrate proteins, the sterile alpha motif, which is shared with certain signalling molecules and the ANK domain, which contains 24 ankyrin repeats homologues to the cytoskeletal protein ankyrin. The ANK domain interacts with a telomeric protein, Telomere Repeat binding Factor-1 (TRF-1). These proteins were therefore named TRF1-interacting, ankyrin-related ADP-ribose polymerase (TANKs).

One of the more specific functions of TANK is the ADP-ribosylation of TRF-1. Human telomere function requires two telomere-specific DNA binding proteins, TRF-1 and TRF-2. TRF-2 protects chromosome ends, and TRF-1 regulates telomere length. ADP-ribosylation inhibits the ability of TRF-1 to bind to telomeric DNA. This poly-ADP-ribosylation of TRF-1 releases TRF-1 from the telomeres, opening up the telomeric complex and allow access to telomerase. Therefore, TANK functions as a positive regulator of telomere length, allowing elongation of the telomeres by telomerase.

Among the many functions attributed to PARP, and especially PARP-1, is its major role in facilitating DNA repair by ADP-ribosylation and therefore coordinating a number of DNA repair proteins. As a result of PARP activation, NAD⁺ levels significantly decline. Extensive PARP activation leads to severe depletion of NAD⁺ in cells suffering from massive DNA damage. The short half-life of poly(ADP-ribose) results in a rapid turnover rate. Once poly(ADP-ribose) is formed, it is quickly degraded by the constitutively active poly(ADP-ribose) glycohydrolase (PARG), together with phosphodiesterase and (ADP-ribose) protein lyase. PARP and PARG form a cycle that converts a large amount of NAD⁺ to ADP-ribose. In less than an hour, over-stimulation of PARP can cause a drop of NAD⁺ and ATP to less than 20% of the normal level. Such a scenario is especially detrimental during ischaemia when deprivation of oxygen has already drastically compromised cellular energy output. Subsequent free radical production during reperfusion is assumed to be a major cause of tissue damage. Part of the ATP drop, which is typical in many organs during ischaemia and reperfusion, could be linked to NAD⁺ depletion due to poly(ADP-ribose) turnover. Thus, PARP or PARG inhibition is expected to preserve the cellular energy level thereby potentiating the survival of ischaemic tissues after insult.

Poly(ADP-ribose) synthesis is also involved in the induced expression of a number of genes essential for inflammatory response. PARP inhibitors suppress production of inducible nitric oxide synthase (iNOS) in macrophages, P-type selectin and intercellular adhesion molecule-1 (ICAM-1) in endothelial cells. Such activity underlies the strong anti-inflammation effects exhibited by PARP inhibitors. PARP inhibition is able to reduce necrosis by preventing translocation and infiltration of neutrophils to the injured tissues.

PARP is activated by damaged DNA fragments and, once activated, catalyzes the attachment of up to 100 ADP-ribose units to a variety of nuclear proteins, including histones and PARP itself. During major cellular stresses the extensive activation of PARP can rapidly lead to cell damage or death through depletion of energy stores. As four molecules of ATP are consumed for every molecule of NAD⁺ regenerated, NAD⁺ is depleted by massive PARP activation, in the efforts to re-synthesize NAD⁺, ATP may also become depleted.

It has been reported that PARP activation plays a key role in both NMDA- and NO-induced neurotoxicity. This has been demonstrated in cortical cultures and in hippocampal slices wherein prevention of toxicity is directly correlated to PARP inhibition potency. The potential role of PARP inhibitors in treating neurodegenerative diseases and head trauma has thus been recognized even if the exact mechanism of action has not yet been elucidated.

Similarly, it has been demonstrated that single injections of PARP inhibitors have reduced the infarct size caused by ischemia and reperfusion of the heart or skeletal muscle in rabbits. In these studies, a single injection of 3-amino-benzamide (10 mg/kg), either one minute before occlusion or one minute before reperfusion, caused similar reductions in infarct size in the heart (32-42%) while 1,5-dihydroxyisoquinoline (1 mg/kg), another PARP inhibitor, reduced infarct size by a comparable degree (38-48%) These results make it reasonable to assume that PARP inhibitors could salvage previously ischaemic heart or reperfusion injury of skeletal muscle tissue.

PARP activation can also be used as a measure of damage following neurotoxic insults resulting from exposure to any of the following inducers like glutamate (via NMDA receptor stimulation), reactive oxygen intermediates, amyloid β-protein, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or its active metabolite N-methyl-4-phenylpyridine (MPP⁺), which participate in pathological conditions such as stroke, Alzheimer's disease and Parkinson's disease. Other studies have continued to explore the role of PARP activation in cerebellar granule cells in vitro and in MPTP neurotoxicity. Excessive neural exposure to glutamate, which serves as the predominate central nervous system neurotransmitter and acts upon the N-methyl D-aspartate (NMDA) receptors and other subtype receptors, most often occurs as a result of stroke or other neurodegenerative processes. Oxygen deprived neurons release glutamate in great quantities during ischaemic brain insult such as during a stroke or heart attack. This excess release of glutamate in turn causes over-stimulation (excitotoxicity) of N-methyl-D-aspartate (NMDA), AMPA, Kainate and MGR receptors, which open ion channels and permit uncontrolled ion flow (e.g., Ca²⁺ and Na⁺ into the cells and K⁺ out of the cells) leading to overstimulation of the neurons. The over-stimulated neurons secrete more glutamate, creating a feedback loop or domino effect which ultimately results in cell damage or death via the production of proteases, lipases and free radicals. Excessive activation of glutamate receptors has been implicated in various neurological diseases and conditions including epilepsy, stroke, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, schizophrenia, chronic pain, ischemia and neuronal loss following hypoxia, hypoglycemia, ischemia, trauma, and nervous insult. Glutamate exposure and stimulation has also been implicated as a basis for compulsive disorders, particularly drug dependence. Evidence includes findings in many animal species, as well as in cerebral cortical cultures treated with glutamate or NMDA, that glutamate receptor antagonists (i.e., compounds which block glutamate from binding to or activating its receptor) block neural damage following vascular stroke. Attempts to prevent excitotoxicity by blocking NMDA, AMPA, Kainate and MGR receptors have proven difficult because each receptor has multiple sites to which glutamate may bind and hence finding an effective mix of antagonists or universal antagonist to prevent binding of glutamate to all of the receptor and allow testing of this theory, has been difficult. Moreover, many of the compositions that are effective in blocking the receptors are also toxic to animals. As such, there is presently no known effective treatment for glutamate abnormalities. The stimulation of NOVA receptors by glutamate, for example, activates the enzyme neuronal nitric oxide synthase (nNOS), leading to the formation of nitric oxide (NO), which also mediates neurotoxicity. NMDA neurotoxicity may be prevented by treatment with nitric oxide synthase (NOS) inhibitors or through targeted genetic disruption of nNOS in vitro.

Another use for PARP inhibitors is the treatment of peripheral nerve injuries, and the resultant pathological pain syndrome known as neuropathic pain, such as that induced by chronic constriction injury (CCI) of the common sciatic nerve and in which transsynaptic alteration of spinal cord dorsal horn characterized by hyperchromatosis of cytoplasm and nucleoplasm (so-called “dark” neurons) occurs.

Evidence also exists that PARP inhibitors are useful for treating inflammatory bowel disorders, such as colitis. Specifically, colitis was induced in rats by intraluminal administration of the hapten trinitrobenzene sulfonic acid in 50% ethanol. Treated rats received 3-aminobenzamide, a specific inhibitor of PARP activity. Inhibition of PARP activity reduced the inflammatory response and restored the morphology and the energetic status of the distal colon.

Further evidence suggests that PARP inhibitors are useful for treating arthritis. Further, PARP inhibitors appear to be useful for treating diabetes. PARP inhibitors have been shown to be useful for treating endotoxic shock or septic shock.

PARP inhibitors have also been used to extend the lifespan and proliferative capacity of cells including treatment of diseases such as skin aging, Alzheimer's disease, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, degenerative diseases of skeletal muscle involving replicative senescence, age-related muscular degeneration, immune senescence, AIDS, and other immune senescence disease; and to alter gene expression of senescent cells.

It is also known that PARP inhibitors, such as 3-amino benzamide, affect overall DNA repair in response, for example, to hydrogen peroxide or ionizing radiation.

The pivotal role of PARP in the repair of DNA strand breaks is well established, especially when caused directly by ionizing radiation or, indirectly after enzymatic repair of DNA lesions induced by methylating agents, topoisomerases I inhibitors and other chemotherapeutic agents as cisplatin and bleomycin. A variety of studies using “knockout” mice, trans-dominant inhibition models (over-expression of the DNA-binding domain), antisense and small molecular weight inhibitors have demonstrated the role of PARP in repair and cell survival after induction of DNA damage. The inhibition of PARP enzymatic activity should lead to an enhanced sensitivity of the tumor cells towards DNA damaging treatments.

PARP inhibitors have been reported to be effective in radiosensitizing (hypoxic) tumor cells and effective in preventing tumor cells from recovering from potentially lethal and sublethal damage of DNA after radiation therapy, presumably by their ability to prevent DNA strand break rejoining and by affecting several DNA damage signaling pathways.

PARP inhibitors have been used to treat cancer. In addition, U.S. Pat. No. 5,177,075 discusses several isoquinolines used for enhancing the lethal effects of ionizing radiation or chemotherapeutic agents on tumor cells. Weltin et al., “Effect of 6(5-Phenanthridinone), an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells”, Oncol. Res., 6:9, 399-403 (1994), discusses the inhibition of PARP activity, reduced proliferation of tumor cells, and a marked synergistic effect when tumor cells are co-treated with an alkylating drug.

Reviews of the state of the art has been published by Li and Zhang in IDrugs 2001, 4(7): 804-812, by Ame et al in Bioassays 2004, 26: 882-883 and by Nguewa et al., in Progress in Biophysic & Molecular Biology 2005, 88: 143-172.

There continues to be a need for effective and potent PARP inhibitors, and more particularly PARP-1 inhibitors which produce minimal side effects. The present invention provides compounds, compositions for, and methods of, inhibiting PARP activity for treating cancer and/or preventing cellular, tissue and/or organ damage resulting from cell damage or death due to, for example, necrosis or apoptosis. The compounds and compositions of the present invention are especially useful in enhancing the effectiveness of chemotherapy and radiotherapy where a primary effect of the treatment is that of causing DNA damage in the targeted cells.

BACKGROUND PRIOR ART

The synthesis of aminophthalazinone derivatives is described by Komendy et al, in Acta Chimica Academiae Scientiarum Hungaricae 1981, 106(2): 155-66 and in Acta Chimica Hungarica 1983, 112(1): 65-82.

EP 156433, published on Oct. 2, 1985 discloses pyridazinamines. The described compounds have anti-viral properties. More in particular compounds No. 77, No. 78, No. 79, No. 80, No. 81, No. 82, No. 83, and No. 84 of the present application are disclosed.

DESCRIPTION OF THE INVENTION

This invention concerns compounds of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein the dotted line represents an optional bond;

-   n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; -   Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and     -   when Q is —CR³— the dotted line represents a bond; -   each X is independently —N< or —CH<; and when X is —CH< then Y is     —N<, or —NH—; -   each Y is independently —N<, —NH—, —CH< or —CH₂—; -   except when X is —CH< then Y is —N<, or —NH—; -   L¹ is a direct bond or a bivalent radical selected from     —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; -   L² is a direct bond or a bivalent radical selected from     —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or     —C₁₋₆alkanediyl-substituted with one substituent selected from     hydroxy or aryl; -   R¹ is hydrogen, nitro, halo or amino; -   R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl;     the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;

-   Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino,     cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or     a ring system selected from

-   -   wherein R⁴ and R⁵ are each independently selected from hydrogen,         halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl;         aryl is phenyl, or phenyl substituted with one or two         substituents each independently selected from halo, C₁₋₆alkyl or         C₁₋₆alkyloxy;         with the proviso that when Q is —C(═O)— and X is —N< and Y is         —CH< or —CH₇— and L¹ is a direct bond and L² is a direct bond,         or the bivalent radical —C₁₋₆alkanediyl- or         —C₁₋₆alkanediyl-substituted with hydroxy and R¹ is hydrogen and         R² is hydrogen or C₁₋₆alkyl then Z is other than hydrogen,         hydroxy or C₁₋₆alkyl; and         when n is 1 and X is —N< and Y is —N< and L¹ and L² are a direct         bond and R¹ and R² are hydrogen and Q is —CR³— wherein R³ is         chloro then Z is other than the ring system (a-3).

The compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

A number of terms used in the foregoing definitions and hereinafter are explained hereunder. These terms are sometimes used as such or in composite terms.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; trihalomethyl defines methyl containing three identical or different halo substituents for example trifluoromethyl; C₁₋₆alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, e.g. methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 2-methylpropyl, 2-methyl-butyl, 2-methylpentyl and the like; —C₁₋₆alkanediyl-defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof such as, 2-methylpentanediyl, 3-methylpentanediyl, 2,2-dimethylbutanediyl, 2,3-dimethylbutanediyl and the like; —C₂₋₆alkenediyl-defines bivalent straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenediyl, 2-propenediyl, 3-butenediyl, 2-pentenediyl, 3-pentenediyl, 3-methyl-2-butenediyl, and the like.

The term “pharmaceutically acceptable salts” means pharmaceutically acceptable acid or base addition salts. The pharmaceutically acceptable acid or base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base addition salt forms which the compounds of formula (I) are able to form. The compounds of formula (I) which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.

The compounds of formula (I) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

The terms acid or base addition salt also comprise the hydrates and the solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The term stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

The N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide, particularly those N-oxides wherein one or more of the piperidine- or piperazine nitrogens are N-oxidized.

Whenever used hereinafter, the term “compounds of formula (I)” is meant to include also the N-oxide forms, the pharmaceutically acceptable acid or base addition salts and all stereoisomeric forms.

In Komendy et al, only the synthesis of aminophthalazinone derivatives is described. The compounds described in EP 156433 have anti-viral properties. More in particular compounds No. 77, No. 78, No. 79, No. 80, No. 81, No. 82, No. 83, and No. 84 of the present application have been disclosed.

Unexpectedly, it has been found that the compounds of the present invention show PARP inhibitory activity.

A first group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply:

-   a) n is 0, 1 or 2; -   b) R² is hydrogen or arylC₁₋₆alkyl; -   c) Z is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino, cyano,     arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or a ring system     selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7),     (a-8), (a-9), (a-10).

A second group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply:

-   a) Q is —CR³— wherein R³ is halo or C₁₋₆alkyl; -   b) each X is —CH<; -   c) each Y is independently —N< or —NH—; -   d) L¹ is a bivalent radical selected from —C₁₋₆alkanediyl-NH—, —NH—     or —NH—C₁₋₆alkanediyl-NH—; -   e) L² is a bivalent radical selected from —C₂₋₆alkenediyl-, carbonyl     or —C₁₋₆alkanediyl-substituted with aryl; -   f) R¹ is nitro, halo or amino; -   g) R² is arylC₁₋₆alkyl; -   h) Z is C₁₋₆alkyloxy, aryloxy, amino, cyano, arylC₁₋₆alkylamino or     benzthiazolyl(C₁alkyl)amino or a ring system selected from (a-1),     (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10).

A third group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply:

-   a) n is 0, 2 or 3; -   b) Q is —C(═O)— or —CR³— wherein R³ is C₁₋₆alkyl; -   c) each X is —CH<; -   d) each Y is independently —CH< or —CH₂—; -   e) L¹ is a bivalent radical selected from —C₁₋₆alkanediyl-NH—, —NH—     or —NH—C₁₋₆alkanediyl-NH—; -   f) L² is a bivalent radical selected from —C₁₋₆alkanediyl-,     —C₂₋₆alkenediyl-, carbonyl or —C₁₋₆alkanediyl-substituted with one     substituent selected from hydroxy or aryl; -   g) R¹ is nitro, halo or amino; -   h) R² is C₁₋₆alkyl or arylC₁₋₆alkyl; -   i) Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino,     cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or a ring     system selected from (a-1), (a-2), (a-4), (a-5), (a-6), (a-7),     (a-8), (a-9), (a-10).

A group of preferred compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply:

-   a) n is 1 or 2; -   b) Q is —C(═O)—; -   c) Y is —N<, —NH— or —CH<; -   c) L¹ is a direct bond or the bivalent radical —NH—; -   d) L² is a direct bond or a bivalent radical selected from carbonyl,     —C₁₋₆alkanediyl- or —C₁₋₆alkanediyl-substituted with hydroxy; -   e) R¹ is hydrogen; -   f) R² is hydrogen, arylC₁₋₆alkyl; -   g) Z is hydrogen, C₁₋₆alkyloxy, aryloxy, amino, or a ring system     selected from (a-2) or (a-3); h) R⁴ and R⁵ are each independently     selected from hydrogen or halo.

A group of most preferred compounds consists of those compounds of formula (I) wherein n is 1 or 2; Q is —C(═O)—; Y is —N<, —NH— or —C(═O)—; L¹ is a direct bond or the bivalent radical —NH—; L² is a direct bond or a bivalent radical selected from carbonyl, —C₁₋₆alkanediyl- or —C₁₋₆alkanediyl-substituted with hydroxy; R¹ is hydrogen; R² is hydrogen, arylC₁₋₆alkyl; Z is hydrogen, C₁₋₆alkyloxy, aryloxy, amino, or a ring system selected from (a-2) or (a-3); and R⁴ and R⁵ are each independently selected from hydrogen or halo.

The most preferred compounds are compounds No. 41, No. 13, No. 62, No. 26, No. 64, No 2 No. 5, No. 9, No. 34, No. 11, No. 15 and No. 10.

The compounds of formula (I) can be prepared according to the general methods described in EP156433. The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art.

Some preparation methods will be described hereinafter in more detail. Other methods for obtaining final compounds of formula (I) are described in the examples.

The compounds of formula (I), wherein L¹ is a bond, X is —CH— and Q is —C(═O)—, herein referred to as compounds of formula (I-a), can be prepared by reacting an intermediate of formula (II), with hydrazine. The reaction can be performed in a suitable solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like.

The compounds of formula (I), wherein Y is —N< and L² is the bivalent radical —C₁₋₆alkanediyl-substituted with hydroxy, herein referred to as compounds of formula (I-b), can be prepared by reacting an intermediate of formula (V), wherein t is an integer with value 0, 1, 2, 3 or 4, with a compound of formula (I), wherein L² is a direct bond and Z is hydrogen, herein referred to as compounds of formula (I-c). The reaction can be performed in a reaction-inert solvent such as, for example,

N,N-dimethylformamide and the like or an alcohol, e.g. propanol and the like. The addition of an appropriate base such as, for example, an alkali or earth alkaline metal carbonate or hydrogen carbonate, e.g. triethylamine or sodium carbonate, may be utilized.

The compounds of formula (I), wherein Y is —N< and L² is the optionally substituted bivalent radical —C₁₋₆alkanediyl-, herein referred to as compounds of formula (I-d), can be prepared by reductively N-alkylating the compounds of formula (I-c), wherein r is an integer with value 0, 1, 2, 3, 4 or 5 with an appropriate carbonyl intermediate of formula (VIII). Said reductive N-alkylation reaction may conveniently be carried out by catalytically hydrogenating a stirred and heated mixture of the reactants in a suitable reaction-inert organic solvent according to art-known catalytic hydrogenating procedures. Suitable solvents are, for example. alcohols, e.g. methanol, ethanol, 2-propanol and the like; cyclic ethers, e.g. 1,4-dioxane and the like; halogenated hydrocarbons, e.g. thrichloromethane and the like; N,N-dimethylformamide; dimethyl sulfoxide and the like; or a mixture of 2 or more of such solvents. The term “art-known catalytic hydrogenating procedures” means that the reaction is carried out under hydrogen atmosphere and in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products it may be advantageous to add appropriate catalyst-poison to the reaction mixture, e.g., thiophene and the like.

Art-known catalytic hydrogenating procedures as described above can also be utilized for the preparation of compounds of formula (I-c) (e.g.), or of compounds of formula I, wherein L² is a direct bond or the bivalent radical —C₁₋₆alkanediyl- and Z is amino, starting from compounds of formula (I) wherein Z-L²- is arylC₁₋₆alkyl (e.g.) or arylC₁₋₆alkylamino, herein referred to as compounds of formula (I-e).

Catalytic hydrogenating procedures can also be utilized for the preparation of compounds of formula (I) wherein Z-L²- is aminoC₁₋₆alkyl, herein referred to as compounds of formula (I-i), by converting compounds of formula (I) wherein Z-L²- is cyano-(CH₂)_(r)— wherein s is an integer with value 1, 2, 3, 4 or 5, herein referred to as compounds of formula (I-j). The reaction is carried out under hydrogen atmosphere and in the presence of Raney Nickel in a mixture of methanol and ammonia.

The compounds of formula (I-c) can also be prepared by deacylating the compounds of formula (I) wherein Z-L²- is —C₁₋₆alkyloxycarbonyl, herein referred to as compounds of formula (I-f), by reacting the starting material with an appropriate acidic or basic solution, such as hydrochloric acid or hydrogen bromide, in a suitable solvent e.g. an alcohol, such as propanol.

The compounds of formula (I), wherein Q is —C(═O)—, herein referred to as compounds of formula (I-g), can be prepared by converting the compounds of formula (I), wherein Q is —CR³—, R³ is halo and the dotted line represents a bond, herein referred to as compounds of formula (I-h), by treatment of a mixture of the compounds of formula (I-h), sodium acetate and acetic acid with an appropriate acidic solution such as hydrochloric acid.

The compounds of formula (I), wherein Y is —N<, herein referred to as compounds of formula (I-k), can be prepared by reacting a compound of formula (I-α), with an intermediate of formula (XI), wherein W is an appropriate leaving group such as, for example, halo, e.g. fluoro, chloro, bromo or iodo, or a sulfonyloxy radical such as methylsulfonyloxy, 4-methylphenylsulfonyloxy and the like. The reaction can be performed in a reaction-inert solvent such as, for example, an alcohol, e.g. methanol, ethanol, 2-methoxy-ethanol, propanol, butanol and the like; an ether, e.g. 4,4-dioxane, 1,1′-oxybispropane and the like; a ketone, e.g. 4-methyl-2-pentanone; N,N-dimethylformamide; or nitrobenzene and the like. The addition of an appropriate base such as, for, example, an alkali or earth alkaline metal carbonate or hydrogen carbonate, e.g. triethylamine or sodium carbonate, may be utilized to pick up the acid which is liberated during the course of the reaction. A small amount of an appropriate metal iodide, e.g., sodium or potassium iodide may be added to promote the reaction. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture and, if desired, the reaction may be carried out at an increased pressure.

In an analogues way, the compounds of formula (I), wherein X is >N— or L¹ is —C₁₋₆alkanediyl-NH—, —NH— (e.g) or —NH—C₁₋₆alkanediyl-NH—, herein referred to as compounds of formula (I-l), can be prepared by reacting an intermediate of formula (IX), with an intermediate of formula (X) wherein W is as described above.

The compounds of formula (I) may also be converted into each other via art-known reactions or functional group transformations. Some of such transformations are already described hereinabove. Other examples are hydrolysis of carboxylic esters to the corresponding carboxylic acid or alcohol; hydrolysis of amides to the corresponding carboxylic acids or amines; hydrolysis of nitriles to the corresponding amides; amino groups on imidazole or phenyl may be replaced by a hydrogen by art-known diazotation reactions and subsequent replacement of the diazo-group by hydrogen; alcohols may be converted into esters and ethers; primary amines may be converted into secondary or tertiary amines; double bonds may be hydrogenated to the corresponding single bond; an iodo radical on a phenyl group may be converted in to an ester group by carbon monoxide insertion in the presence of a suitable palladium catalyst.

Intermediates of formula (II) can be prepared by reacting an intermediate of formula (III) with a suitable 1(3H)-isobenzofuranone of formula (IV) in a mixture of sodium and a suitable solvent such as for example, an alcohol, e.g. ethanol and the like.

The present invention also relates to compounds for use as a medicine wherein said compounds are compounds of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein the dotted line represents an optional bond;

-   n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; -   Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and     -   when Q is —CR³— the dotted line represents a bond; -   each X is independently —N< or —CH<; and when X is —CH< then Y is     —N<, or —NH—; -   each Y is independently —N<, —NH—, —CH< or —CH₂—; -   except when X is —CH< then Y is —N<, or —NH—; -   L¹ is a direct bond or a bivalent radical selected from     —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; -   L² is a direct bond or a bivalent radical selected from     —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or     —C₁₋₆alkanediyl-substituted with one substituent selected from     hydroxy or aryl; -   R¹ is hydrogen, nitro, halo or amino; -   R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl;     the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;

-   Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino,     cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or     a ring system selected from

-   -   wherein R⁴ and R⁵ are each independently selected from hydrogen,         halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl;         aryl is phenyl, or phenyl substituted with one or two         substituents each independently selected from halo, C₁₋₆alkyl or         C₁₋₆alkyloxy;         with the proviso that when n is 1 and X is —N< and Y is —N< and         L¹ and L² are a direct bond and R¹ and R² are hydrogen and Q is         —CR³— wherein R³ is chloro then Z is other than the ringsystem         (a-3).

The compounds of the present invention have PARP inhibiting properties as can be seen from the experimental part hereinunder.

The term “PARP” is used herein to mean a protein having poly-ADP-ribosylation activity. Within the meaning of this term, PARP encompass all proteins encoded by a parp gene, mutants thereof, and alternative slice proteins thereof. Additionally, as used herein, the term “PARP” includes PARP analogues, homologues and analogues of other animals.

The term “TARP”, includes but is not limited to PARP-1. Within the meaning of this term PARP-2, PARP-3, Vault-PARP (PARP-4), PARP-7 (TiPARP), PARP-8, PARP-9 (Bal), PARP-10, PARP-11, PARP-12, PARP-13, PARP-14, PARP-15, PARP-16, TANK-1, TANK-2, and TANK-3 may be encompassed.

Compounds that inhibit both PARP-1 and tankyrase 2 can have advantageous properties in that they have enhanced growth inhibiting activities in cancer cells.

The present invention also contemplates the use of compounds in the preparation of a medicament for the treatment of any of the diseases and disorders in an animal described herein, wherein said compounds are compounds of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo chemically isomeric forms thereof, wherein the dotted line represents an optional bond;

-   n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; -   Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and     -   when Q is —CR³— the dotted line represents a bond; -   each X is independently —N< or —CH<; and when X is —CH< then Y is     —N<, or —NH—; -   each Y is independently —N<, —NH—, —CH< or —CH₂—; -   except when X is —CH< then Y is —N<, or —NH—; -   L¹ is a direct bond or a bivalent radical selected from     —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; -   L² is a direct bond or a bivalent radical selected from     —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or     —C₁₋₆alkanediyl-substituted with one substituent selected from     hydroxy or aryl; -   R¹ is hydrogen, nitro, halo or amino; -   R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl;     the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;

-   Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino,     cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or     a ring system selected from

-   -   wherein R⁴ and R⁵ are each independently selected from hydrogen,         halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl; and         aryl is phenyl, or phenyl substituted with one or two         substituents each independently selected from halo, C₁₋₆alkyl or         C₁₋₆alkyloxy.

In view of their PARP binding properties the compounds of the present invention may be used as reference compounds or tracer compounds in which case one of the atoms of the molecule may be replaced with, for instance, a radioactive isotope.

To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The compounds of the present invention can treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis; can ameliorate neural or cardiovascular tissue damage, including that following focal ischemia, myocardial infarction, and reperfusion injury; can treat various diseases and conditions caused or exacerbated by PARP activity; can extend or increase the lifespan or proliferative capacity of cells; can alter the gene expression of senescent cells; can radiosensitize and/or chemosensitize cells. Generally, inhibition of PARP activity spares the cells from energy loss, preventing, in the case of neural cells, irreversible depolarization of the neurons, and thus, provides neuroprotection.

For the foregoing reasons, the present invention further relates to a method of administering a therapeutically effective amount of the above-identified compounds in an amount sufficient to inhibit PARP activity, to treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis, to effect a neuronal activity not mediated by NMDA toxicity, to effect a neuronal activity mediated by NMDA toxicity, to treat neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related muscular degeneration, AIDS and other immune senescence diseases, inflammation, gout, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging, to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; chemosensitize and/or radiosensitize (hypoxic) tumor cells. The present invention also relates to treating diseases and conditions in an animal which comprises administering to said animal a therapeutically effective amount of the above-identified compounds.

In particular, the present invention relates to a method of treating, preventing or inhibiting a neurological disorder in an animal, which comprises administering to said animal a therapeutically effective amount of the above-identified compounds. The neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic brain injury, physical damage to the spinal cord, stroke associated with brain damage, focal ischemia, global ischemia, reperfusion injury, demyelinating disease and neurological disorder relating to neurodegeneration.

The present invention also contemplates the use of compounds of formula (I) for inhibiting PARP activity, for treating, preventing or inhibiting tissue damage resulting from cell damage or death due to necrosis or apoptosis, for treating, preventing or inhibiting a neurological disorder in an animal.

The term “preventing neurodegeneration” includes the ability to prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease, or at risk of developing a new degenerative disease and for preventing further neurodegeneration in patients who are already suffering from or have symptoms of a neurodegenerative disease.

The term “treatment” as used herein covers any treatment of a disease and/or condition in an animal, particularly a human, and includes: (i) preventing a disease and/or condition from occurring in a subject which may be predisposed to the disease and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease and/or condition, i.e., arresting its development; (iii) relieving the disease and/or condition, i.e., causing regression of the disease and/or condition.

The term “radiosensitizer”, as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to ionizing radiation and/or to promote the treatment of diseases which are treatable with ionizing radiation. Diseases which are treatable with ionizing radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells. Ionizing radiation treatment of other diseases not listed herein are also contemplated by the present invention.

The term “chemosensitizer”, as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of cells to chemotherapy and/or promote the treatment of diseases which are treatable with chemotherapeutics. Diseases which are treatable with chemotherapy include neoplastic diseases, benign and malignant tumors and cancerous cells. Chemotherapy treatment of other diseases not listed herein are also contemplated by the present invention.

The compounds, compositions and methods of the present invention are particularly useful for treating or preventing tissue damage resulting from cell death or damage due to necrosis or apoptosis.

The compounds of the present invention can be “anti-cancer agents”, which term also encompasses “anti-tumor cell growth agents” and “anti-neoplastic agents”. For example, the methods of the invention are useful for treating cancers and chemosensitizing and/or radiosensitizing tumor cells in cancers such as ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

Hence the compounds of the present invention can be used as “radiosensitizer” and/or “chemosensitizer”.

Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of ionizing radiation. Several mechanisms for the mode of action of radiosensitizers have been suggested in the literature including: hypoxic cell radiosensitizers (e.g., 2-nitroimidazole compounds, and benzotriazine dioxide compounds) mimicking oxygen or alternatively behave like bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., halogenated pyrimidines) can be analogs of DNA bases and preferentially incorporate into the DNA of cancer cells and thereby promote the radiation-induced breaking of DNA molecules and/or prevent the normal DNA repair mechanisms; and various other potential mechanisms of action have been hypothesized for radiosensitizers in the treatment of disease. Many cancer treatment protocols currently employ radiosensitizers in conjunction with radiation of x-rays. Examples of x-ray activated radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.

Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent. Examples of photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, tin etioporphyrin, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.

Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of radiosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor with or without additional radiation; or other therapeutically effective compounds for treating cancer or other disease. Examples of additional therapeutic agents that may be used in conjunction with radiosensitizers include, but are not limited to: 5-fluorouracil, leucovorin, 5′-amino-5′deoxythymidine, oxygen, carbogen, red cell transfusions, perfluorocarbons (e.g., Fluosol 10 DA), 2,3-DPG, BW12 C, calcium channel blockers, pentoxyfylline, antiangiogenesis compounds, hydralazine, and LBSO. Examples of chemotherapeutic agents that may be used in conjunction with radiosensitizers include, but are not limited to: adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, docetaxel, doxorubicin, interferon (alpha, beta, gamma), interleukin 2, irinotecan, paclitaxel, topotecan, and therapeutically effective analogs and derivatives of the same.

Chemosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of chemosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor or other therapeutically effective compounds for treating cancer or other disease. Examples of additional therapeutical agents that may be used in conjunction with chemosensitizers include, but are not limited to: methylating agents, topoisomerase I inhibitors and other chemotherapeutic agents such as cisplatin and bleomycin.

The compounds of formula (I) can also be used to detect or identify the PARP, and more in particular the PARP-1 receptor. For that purpose the compounds of formula (I) can be labeled. Said label can be selected from the group consisting of a radioisotope, spin label, antigen label, enzyme label fluorescent group or a chemiluminiscent group.

Those skilled in the art could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective amount would be from 0.001 mg/kg to 100 mg/kg body weight, and in particular from 0.005 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 to 500 mg, and in particular 0.1 mg to 200 mg of active ingredient per unit dosage form.

The following examples illustrate the present invention.

Experimental Part

Hereinafter, “DCM” is defined as dichloromethane, “DIPE” is defined as diisopropyl ether, “DMF” is defined as N,N-dimethylformamide, “EtOH” is defined as ethanol, “EtOAc” is defined as ethyl acetate, “MeOH” is defined as methanol and “TEA” is defined as triethylamine, “THF” is defined as tetrahydrofuran.

A. Preparation of the Intermediate Compounds EXAMPLE A1 Preparation of Intermediate 1

1-(Phenylmethyl)-4-piperidinone (0.2 mol) and 1(3H)-isobenzofuranone (0.2 mol) were added to a dissolved mixture of sodium (0.2 mol) in EtOH absolute (400 ml). The mixture was warmed till reflux and refluxed overnight. The mixture was evaporated, water was added and extracted with toluene. The aqueous layer was neutralized with acetic acid and extracted with DCM. The organic layer was dried, filtered off and evaporated, yielding 30.3 g (51.7%) of intermediate 1.

EXAMPLE A2 a) Preparation of Intermediate 2

Tetrakis(isopropanolato)titanium (50 ml) was added at room temperature to a mixture of 4-oxo-2-(phenylmethyl)-1-piperidinecarboxylic acid, ethyl ester (0.14 mol) and benzylamine (0.14 mol) in EtOH (300 ml) and the mixture was stirred at room temperature for 6 hours. A solution of sodium hydroborate (5.3 g) in EtOH (150 ml) was added and the mixture was stirred at room temperature for 18 hours. The mixture was hydrolized with water, filtered through celite and evaporated. The residue was taken up in DCM and washed with water. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (38.5 g) was purified by column chromatography over silica gel (20-45 μm) (eluent: cyclohexane/EtOAc 60/40). The pure fractions were collected and the solvent was evaporated, yielding 10 g (27%) of intermediate 2.

b) Preparation of Intermediate 3

Intermediate 2 (0.0571 mol) in ETOH (300 ml) was hydrogenated at 50° C. with Pd/C (10 g) as a catalyst for one night under a 3 bar pressure in a Parr apparatus. After uptake of H₂ (1 eq), the catalyst was filtered through celite, washed with EtOH and the filtrate was evaporated, yielding 13.4 g (93%) of intermediate 3.

B. Preparation of the final compounds

EXAMPLE B1 Preparation of Compound 1

A mixture of intermediate 1 (0.098 mol) and hydrazine, monohydrate (0.22 mol) in EtOH (350 ml) was stirred and refluxed overnight. The mixture was evaporated, water was added and extracted with DCM. The organic layer was dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent: CHCl₃/MeOH 98.5/1.5). The pure fractions were collected and evaporated. A part (2.5 g) of the residue (10.5 g, 33.5%) was crystallized from 2-propanol, yielding 1.5 g (20.1%) of compound 1, melting point 222° C.

EXAMPLE B2 a) Preparation of Compound 23

A mixture of compound 1 (0.028 mol) in MeOH (150 ml) was hydrogenated with Pd/C 10% (2 g) as a catalyst at 50° C. After uptake of H₂ (1 eq), the catalyst was filtered over hyflo and the filtrate was evaporated, yielding 6.8 g (100%) of compound 23.

b) Preparation of Compound 2

A mixture of [(4-fluorophenoxy)methyl]-oxirane (0.011 mol) and compound 23 (0.01 mol) in 2-propanol (150 ml) was stirred and refluxed overnight. The mixture was cooled with stirring and crystallized. The precipitate was filtered off and dried, yielding 2.4 g (60.3%) of compound 2, melting point 226.9° C.

EXAMPLE B3 a) Preparation of Compound 15

A mixture of compound 11 (0.08 mol) in hydrobromic acid 48% aqueous (400 ml) was stirred and refluxed for 30 min. The solvent was evaporated. The residue was stirred in 2-propanol (300 ml), filtered off and dried. A part (2 g) of the residue (28 g) was recrystallized from MeOH. The precipitate was filtered off and dried, yielding 0.8 g (40%) of compound 15, isolated as a hydrobromic acid salt, melting point >299° C.

b) Preparation of Compound 3

A mixture of 4-fluoro-y-(4-fluorophenyl)-benzenebutanal (0.045 mol), compound 15 (0.045 mol) and potassium acetate (6 g) in MeOH (250 ml) was hydrogenated, overnight at 50° C., with Pd/C 10% (3 g) as a catalyst in the presence of thiophene 4% solution (1 ml). After uptake of H₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in DCM. The organic solution was washed with aqueous ammonia, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: DCM/MeOH 96/4). The desired fractions were collected and the solvent was evaporated. A part (3 g) of the residue (18 g, 78%) was dissolved in 2-propanol and converted into the (E)-2-butenedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 2.9 g (60%) of compound 3, melting point 164.4° C.

EXAMPLE B4 Preparation of Compound 4

A mixture of compound 1 (0.028 mol) in MeOH (150 ml) was hydrogenated with Pd/C 10% (2 g) as a catalyst at 50° C. After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was evaporated. A part (1.5 g) of the residue (6.8 g, 100%) was dissolved in 2-propanol and converted into the (E)-2-butenedioic acid salt (2:1) in 2-propanol, yielding 0.7 g (37.2%) of compound 4, melting point 264.9° C.

EXAMPLE B5 Preparation of Compound 5

Acetic acid, anhydride (0.00523 mol) was added dropwise at room temperature to a mixture of compound 4 (0.00436 mol) and TEA (0.00872 mol) in DCM (10 ml). The mixture was stirred at room temperature for 2 hours and poured out into ice water. DCM was added. The mixture was acidified with HCl 1N and extracted with DCM. The organic layer was separated, basified with potassium carbonate 10%, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1 g, 85%) was crystallized from acetonitrile. The precipitate was filtered off and dried in vacuo, yielding 0.88 g (75%) of compound 5, melting point 222° C.

EXAMPLE B6 Preparation of compound 6

Isocyanatotrimethyl-silane (0.00523 mol) was added dropwise at room temperature to a mixture of compound 4 (0.00436 mol) in DCM (20 ml). The mixture was stirred at room temperature for 2 hours. The solvent was evaporated till dryness. The residue was taken up in warm MeOH. The precipitate was filtered off and dried in vacuo. The residue (0.8 g, 67%) was taken up in MeOH and DCM. The mixture was stirred. The precipitate was filtered off and dried in vacuo, yielding 0.55 g (46%) of compound 6, melting point >300° C.

EXAMPLE B7 Preparation of Compound 7

A mixture of compound 4 (0.013 mol), chloro-acetonitrile (0.014 mol) and sodium carbonate (0.065 mol) in DMF (150 ml) was stirred at 70° C. for 3 hours, cooled, poured out into ice water and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated till dryness. The residue (6.1 g) was purified by column chromatography over silica gel (15-40 μm) (eluent: DCM/MeOH/NH₄OH 98/2/0.1). The pure fractions were collected and the solvent was evaporated. The residue was taken up in MeOH. The precipitate was filtered off and dried, yielding 0.33 g (10%) of compound 7, melting point 259° C.

EXAMPLE B8 Preparation of Compound 8

A mixture of compound 7 (0.0027 mol) in MeOH/NH₃ 7N (30 ml) was hydrogenated under a 3 bar pressure for 24 hours with raney nickel (0.73 g) as a catalyst. After uptake of H₂ (2 equiv), the catalyst was filtered through celite and the filtrate was evaporated. The residue (0.48 g) was purified by column chromatography over silica gel (15-40 μm) (eluent: DCM/MeOH/NH₄OH 85/14/1 to 83/15/2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.3 g (40.5%) of compound 8, melting point 202° C.

EXAMPLE B9 a) Preparation of Compound 17

A mixture of 1,4-dichlorophthalazine (0.05 mol), 4-piperidinecarbonitrile, monohydrochloride (0.045 mol) and sodium carbonate (0.301 mol) in DMF (100 ml) was stirred at 130° C. for 5 hours, poured out into ice water and extracted with EtOAc. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated till dryness. The residue (16 g) was purified by column chromatography over silica gel (20-45 μm) (eluent: DCM/MeOH 98/2). The pure fractions were collected and the solvent was evaporated, yielding 7.5 g (61.1%) of compound 17.

b) Preparation of Compound 18

A mixture of compound 17 (0.024 mol) and sodium acetate (0.036 mol) in acetic acid (77 ml) was stirred and refluxed for 2 hours. The solvent was evaporated till dryness. The residue was taken up in water. The mixture was basified with potassium carbonate solid. DCM was added. A solid was filtered off and dried, yielding 4.67 g (76%) of compound 18, melting point 253° C.

Preparation of Compound 9

A mixture of compound 18 (0.016 mol) in MeOH/NH₃ 7N (150 ml) was hydrogenated at room temperature under a 3 bar pressure for 18 hours with raney nickel (4.2 g) as a catalyst. After uptake of H₂ (2 equiv), the catalyst was filtered through celite and the filtrate was evaporated till dryness. The residue (5.3 g) was purified by column chromatography over silica gel (15-40 μm) (eluent: DCM/MeOH/NH₄OH 88/12/1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding: 2.8 g (67.7%) of compound 9, melting point 182° C.

EXAMPLE B 10 a) Preparation of compound 19

A mixture of 1,4-dichlorophthalazine (0.00502 mol), intermediate 3 (0.00452 mol) and sodium carbonate (0.01004 mol) in DMF (15 ml) was stirred at 130° C. for 5 hours, brought to room temperature, poured out into ice water and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1.2 g) was purified by column chromatography over silica gel (15-40 μm)(eluent: DCM/MeOH(NH₄OH 99/1/0.1 to 85/15/0.1). The pure fractions were collected and the solvent was evaporated. The residue (0.7 g, 33%) was crystallized from acetonitrile and diethyl ether. The precipitate was filtered off and dried in vacuo, yielding 0.32 g (15%) of compound 19, melting point 161° C.

b) Preparation of Compound 16

A mixture of compound 19 (0.0087 mol) and sodium acetate (0.01306 mol) in acetic acid (40 ml) was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. Hydrochloric acid 10% (40 ml) was added. The mixture was stirred and refluxed for 1 hour and then brought to room temperature. DCM was added. The mixture was basified with diluted NH₄OH solution and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (15-40 μm) (eluent: DCM/MeOH 97.5/2.5). The desired fractions were collected and the solvent was evaporated. The residue (1.4 g, 40%) was crystallized from diethyl ether. The precipitate was filtered off and dried in vacuo, yielding 0.95 g (27%) of compound 16, melting point 140° C.

c) Preparation of Compound 10

A mixture of compound 16 (0.00492 mol) in HCl 12N (50 ml) was stirred and refluxed overnight and then brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in EtOAc. The mixture was basified with potassium carbonate 10% and extracted with EtOAc and a small amount of EtOH. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was taken up in acetonitrile. The precipitate was filtered off and dried in vacuo, yielding 1.29 g (79%) of compound 10, melting point 238° C.

EXAMPLE B11 a) Preparation of Compound 24

A mixture of 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylic acid, ethyl ester (0.25 mol), 1,4-dichlorophthalazine (0.25 mol) and sodium carbonate (0.25 mol) in DMF (600 ml) was stirred for 4 hours at 130° C. The reaction mixture was cooled and poured out into water. The precipitate was filtered off, washed with water, then dissolved in DCM. The organic solution was dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from 2-propanol/DIPE. The precipitate was filtered off and dried, yielding 65 g (72%) of compound 24.

b) Preparation of Compound 11

A mixture of compound 24 (0.16 mol) and sodium acetate (0.16 mol) in acetic acid (800 ml) was stirred and refluxed for 5 hours. The solvent was evaporated. Hydrochloric acid 10% (800 ml) was added to the residue and the reaction mixture was stirred and refluxed for 1 hour, then cooled to room temperature and the resulting precipitate was filtered off, washed with water, then dried. A part (4 g) of the residue (30 g) was crystallized from 2-propanol. The precipitate was filtered off and dried, yielding 2.5 g (34%) of compound 11, melting point 218.6° C.

EXAMPLE B12 Preparation of Compound 12

A mixture of 1,4-dichlorophthalazine (0.13 mol), 1-(phenylmethyl)-3-pyrrolidinamine (0.12 mol) and sodium carbonate (0.26 mol) in DMF (150 ml) was stirred under N₂ at 130° C. for 4 hours. The mixture was cooled, poured into ice and extracted with DCM. The organic layer was washed with a saturated NaCl solution, dried (MgSO₄), filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent: DCM/MeOH 100/0 to 97/3). The pure fractions were collected and evaporated. A part of the residue (38 g, 93.5%) was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:2) in 2-propanol, yielding 2.43 g of compound 12, melting point 171.8° C.

EXAMPLE B 13 Preparation of Compound 13

A mixture of 1-(3-chloropropoxy)-4-fluoro-benzene (0.025 mol), compound 23 (0.02 mol) and sodium carbonate (0.06 mol) in DMF (150 ml) was stirred at 60° C. for 12 h. The mixture was cooled, poured into ice water, acidified with HCl and neutralized with NH₃. The precipitate was filtered off and crystallized from MeOH. The precipitate was filtered off and dried at 60° C. The residue (2.1 g) was converted into the hydrochloric acid salt (1:1) in 2-propanol. The precipitate was filtered off and washed with 2-propanol and DIPE. The residue was dried at room temperature, yielding 1.2 g (14.4%) of compound 13, melting point 227.6° C.

EXAMPLE B 14 a) Preparation of Compound 20

A mixture of 1,4-dichloro-6-nitro-phthalazine (0.0557 mol), 4-amino-1-piperidinecarboxylic acid, ethyl ester (0.0501 mol) and sodium carbonate (0.0836 mol) in DMF (150 ml) was stirred at 130° C. overnight and then brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in DCM. The mixture was poured out into ice water and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (20-45 μm) (eluent: DCM/MeOH/NH₄OH 98/2/0.4). The pure fractions were collected and the solvent was evaporated. The residue (6.5 g) was crystallized from diethyl ether. The precipitate was filtered off and dried in vacuo, yielding 6.2 g (29%) of compound 20, melting point 199° C.

b) Preparation of Compound 21

A mixture of compound 20 (0.0155 mol) and sodium acetate (0.0233 mol) in acetic acid (50 ml) was stirred and refluxed for 3 hours. The solvent was evaporated till dryness. Hydrochloric acid 10% (50 ml) was added. The mixture was stirred and refluxed for 1 hour, brought to room temperature, poured out into ice water, basified with a concentrated NH₄OH solution and stirred. The precipitate was filtered off, washed with water, washed with 2-propanone and diethyl ether and dried in vacuo, yielding 5.3 g (95%) of compound 21, melting point 286° C.

c) Preparation of Compound 22

A mixture of compound 21 (0.11 mol) in hydrochloric acid 10N (100 ml) was stirred and refluxed overnight and brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in MeOH and EtOH. The mixture was stirred. The precipitate was filtered off and dried in vacuo, yielding 3.5 g (98%) of compound 22, melting point 300° C.

d) Preparation of Compound 14

N₂ was bubbled through a mixture of compound 22 (0.00614 mol) in MeOH (30 ml) and THF (30 ml). Raney nickel (2 g) was added portionwise. N₂ was bubbled through the mixture. The mixture was hydrogenated at room temperature under 3 bar pressure for 2 hours. After uptake of H₂ (3 equiv), the catalyst was filtered through celite, washed with DCM and MeOH and the filtrate was evaporated till dryness. The residue was taken up in MeOH and EtOH. The precipitate was filtered off and dried in vacuo. The residue was taken up in warm MeOH. The precipitate was filtered off and dried in vacuo, yielding 0.47 g (24%) of compound 14, melting point >300° C.

Table F-1 lists the compounds that were prepared according to one of the above Examples.

TABLE F-1

Co. No. 1; Ex. [B1]; mp. 222° C.

Co. No. 2; Ex. [B2]; mp. 226.9° C.

•C₄H₄O₄•H₂O; (ENDO); Co. No. 3; Ex. [B3]; mp. 164.4° C.

•1/2 C₄H₄O₄•1/2 H₂O; Co. No. 4; Ex. [B4]; mp. 264.9° C.

Co. No. 5; Ex. [B5]; mp. 222° C.

Co. No. 6; Ex. [B6]; mp. >300° C.

Co. No. 7; Ex. [B7]; mp. 259° C.

Co. No. 8; Ex. [B8]; mp. 202° C.

Co. No. 9; Ex. [B9]; mp. 182° C.

(CIS); Co. No. 10; Ex. [B10]; mp. 238° C.

(ENDO); Co. No. 11; Ex. [B11]; mp. 218.6° C.

•2 HCl•H₂O; Co. No. 12; Ex. [B12]; mp. 171.8° C.

•HCl; Co. No. 13; Ex. [B13]; mp. 227.6° C.

•HCl•H₂O; Co. No. 14; Ex. [B14]; mp. >300° C.

•HBr; (ENDO); Co. No. 15; Ex. [B3]; mp. >299° C.

(CIS); Co. No. 16; Ex. [B10]; mp. 140° C.

Co. No. 23; Ex. [B2]

Co. No. 17; Ex. [B9]

Co. No. 18; Ex. [B9]; mp. 253° C.

CIS; Co. No. 19; Ex. [B10]; mp. 161° C.

Co. No. 24; Ex. [B11]

Co. No. 20; Ex. [B14]; mp. 199° C.

Co. No. 21; Ex. [B14]; mp. 286° C.

Co. No. 22; Ex. [B14]; mp. 300° C.

Co. No. 25; Ex. [B1]; mp. 228.4° C.

Co. No. 26; Ex. [B2]; mp. 214.6° C.

[S-(R*, S*)]; Co. No. 27; Ex. [B2]; mp. 232.7° C.

•HCl; [S-(R*, S*)]; Co. No. 28; Ex. [B2]

•2 HCl; Co. No. 29; Ex. [B3]

Co. No. 30; Ex. [B3]; mp. 163.7° C.

Co. No. 31; Ex. [B4]; mp. 177° C.

Co. No. 32; Ex. [B7]; mp. 230° C.

Co. No. 33; Ex. [B8]; mp. 250° C.

•2 HBr; Co. No. 34; Ex. [B10]

(TRANS); Co. No. 35; Ex. [B10]; mp. 110° C.

•2 HCl; Co. No. 36; Ex. [B10]; mp. 248° C.

•2HCl•H₂O; Co. No. 37; Ex. [B10]; mp. 240° C.

Co. No. 38; Ex. [B10]; mp. 218° C.

•2 HCl•H₂O; Co. No. 39; Ex. [B10]; mp. >260° C.

•2 HCl; Co. No. 40; Ex. [B10]; mp. 260° C.

•2 HBr; Co. No. 41; Ex. [B10]

Co. No. 42; Ex. [B11]; mp. 194° C.

Co. No. 43; Ex. [B11]; mp. 227° C.

•C₄H₄O₄; Co. No. 44; Ex. [B11]; mp. 207.8° C.

Co. No. 45; Ex. [B11]; mp. 205° C.

•HCl•H₂O; Co. No. 46; Ex. [B11]; mp. 253.1° C.

Co. No. 47; Ex. [B11]; mp. 182° C.

Co. No. 48; Ex. [B11]

•2 C₄H₄O₄; Co. No. 49; Ex. [B11]; mp. 131.5° C.

Co. No. 50; Ex. [B11]; mp. 177.9° C.

Co. No. 51; Ex. [B11]; mp. 221.1° C.

•HCl; Co. No. 52; Ex. [B11]; mp. 150.6° C.

•HCl•H₂O; Co. No. 53; Ex. [B11]; mp. 208.4° C.

Co. No. 54; Ex. [B11]; mp. 270.8° C.

Co. No. 55; Ex. [B11]; mp. 170.9° C.

Co. No. 56; Ex. [B11]; mp. 224.5° C.

•C₄H₄O₄; Co. No. 57; Ex. [B12]; mp. 190.2° C.

Co. No. 58; Ex. [B12]; mp. 168° C.

•2 HCl•2 H₂O; Co. No. 59; Ex. [B12]; mp. 234.4° C.

•C₄H₄O₄; (ENDO); Co. No. 60; Ex. [B12]; mp. 178.5° C.

Co. No. 61; Ex. [B12]; mp. 183.5° C.

•HCl•1/2 H₂O•1/2 C₃H₈O; Co. No. 62; Ex. [B13]; mp. 277.7° C.

•2 HCl•H₂O; Co. No. 63; Ex. [B13]; mp. 289.2° C.

•HCl; Co. No. 64; Ex. [B13]; mp. 288.5° C.

•2 HCl•1/2 H₂O; (E); Co. No. 65; Ex. [B13]; mp. 225.7° C.

(E); Co. No. 66; Ex. [B13]; mp. 203.1° C.

•HCl•1/2 H₂O; Co. No. 67; Ex. [B13]; mp. 218.3° C.

Co. No. 68; Ex. [B13]; mp. 161.9° C.

Co. No. 69; Ex. [B13]; mp. 251.8° C.

Co. No. 70; Ex. [B13]; mp. >300° C.

Co. No. 71; Ex. [B13]; mp. 274.1° C.

Co. No. 72; Ex. [B13]; mp. 186.5° C.

Co. No. 73; Ex. [B13]; mp. 203° C.

Co. No. 74; Ex. [B13]; mp. 184.6° C.

Co. No. 75; Ex. [B13]; mp. 202.6° C.

Co. No. 76; Ex. [B13]; mp. 198.8° C.

Co. No. 77; EP156433

Co. No. 78; EP156433

Co. No. 79; EP156433

Co. No. 80; EP156433

Co. No. 81; EP156433

Co. No. 82; EP156433

Co. No. 83; EP156433

Co. No. 84; EP156433

PHARMACOLOGICAL EXAMPLE In vitro Scintillation Proximity Assay (SPA) for PARP-1 Inhibitory Activity

Compounds of the present invention were tested in an in vitro assay based on SPA technology (proprietary to Amersham Pharmacia Biotech).

In principle, the assay relies upon the well established SPA technology for the detection of poly(ADP-ribosylation of biotinylated target proteins, i.e histones. This ribosylation is induced using nicked DNA activated PARP-1 enzyme and [³H]-nicotinamide adenine dinucleotide ([³H]-NAD⁺) as ADP-ribosyl donor.

As inducer of PARP-1 enzyme activity, nicked DNA was prepared. For this, 25 mg of DNA (supplier: Sigma) was dissolved in 25 ml DNAse buffer (10 mM Tris-HCl, pH 7.4; 0.5 mg(ml Bovine Serum Albumine (BSA); 5 mM MgCl₂.6H₂O and 1 mM KCl) to which 50 Al DNAse solution (1 mg/ml in 0.15 M NaCl) was added. After an incubation of 90 min. at 37° C., the reaction was terminated by adding 1.45 g NaCl, followed by a further incubation at 58° C. for 15 min. The reaction mixture was cooled on ice and dialysed at 4° C. for respectively 1.5 and 2 hours against 1.51 of 0.2 M KCl, and twice against 1.51 of 0.01 M KCl for 1.5 and 2 h respectively. The mixture was aliquoted and stored at −20° C. Histones (1 mg/ml, type II-A, supplier: Sigma) were biotinylated using the biotinylation kit of Amersham and stored aliquoted at −20° C. A stock solution of 100 mg/ml SPA poly(vinyl toluene) (PVT) beads (supplier: Amersham) was made in PBS. A stock solution of [³H]-NAD⁺ was made by adding 120 μl of [³H]-NAD⁺ (0.1 mCi/ml, supplier: NEN) to 6 ml incubation buffer (50 mM Tris/HCl, pH 8; 0.2 mM DTT; 4 mM MgCl₂). A solution of 4 mM NAD⁺ (supplier: Roche) was made in incubation buffer (from a 100 mM stock solution in water stored at −20° C.). The PARP-1 enzyme was produced using art known techniques, i.e. cloning and expression of the protein starting from human liver cDNA. Information concerning the used protein sequence of the PARP-1 enzyme including literature references can be found in the Swiss-Prot database under primary accession number P09874. Biotinylated histones and PVT-SPA beads were mixed and pre-incubated for 30 min. at room temperature. PARP-1 enzyme (concentration was lot dependent) was mixed with the nicked DNA and the mixture was pre-incubated for 30 min. at 4° C. Equal parts of this histones/PVT-SPA beads solution and PARP-1 enzyme/DNA solution were mixed and 75 μl of this mixture together with 1 μl of compound in DMSO and 25 μl of [³H]-NAD⁺ was added per well into a 96-well microtiterplate. The final concentrations in the incubation mixture were 2 μg/ml for the biotinylated histones, 2 mg/ml for the PVT-SPA beads, 2 μg/ml for the nicked DNA and between 5-10 μg/ml for the PARP-1 enzyme. After incubation of the mixture for 15 min. at room temperature, the reaction was terminated by adding 100 μl of 4 mM NAD⁺ in incubation buffer (final concentration 2 mM) and plates were mixed.

The beads were allowed to sediment for at least 15 min. and plates transferred to a TopCountNXT™ (Packard) for scintillation counting, values were expressed as counts per minute (cpm). For each experiment, controls (containing PARP-1 enzyme and DMSO without compound), a blank incubation (containing DMSO but no PARP-1 enzyme or compound) and samples (containing PARP-1 enzyme and compound dissolved in DMSO) were run in parallel. All compounds tested were dissolved and eventually further diluted in DMSO. In first instance, compounds were tested at a concentration of 10⁻⁵ M. When the compounds showed activity at 10⁻⁵ M, a dose-response curve was made wherein the compounds were tested at concentrations between 10⁻⁵M and 10⁻⁸M. In each test, the blank value was subtracted from both the control and the sample values. The control sample represented maximal PARP-1 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the controls. When appropriate, IC₅₀-values (concentration of the drug, needed to reduce the PARP-1 enzyme activity to 50% of the control) were computed using linear interpolation between the experimental points just above and below the 50% level. Herein the effects of test compounds are expressed as pIC₅₀ (the negative log value of the IC₅₀-value). As a reference compound, 4-amino-1,8-naphthalimide was included to validate the SPA assay. The tested compounds showed inhibitory activity at the initial test concentration of 10⁻⁵ M (see Table-2).

In Vitro Filtration Assay for PARP-1 Inhibitory Activity

Compounds of the present invention were tested in an in vitro filtration assay assessing PARP-1 activity (triggered in the presence of nicked DNA) by means of its histone poly (ADP-ribosylation activity using [³²P]-NAD as ADP-ribosyl donor. The radioactive ribosylated histones were precipitated by trichloroacetic acid (TCA) in 96-well filterplates and the incorporated [³²P] measured using a scintillation counter

A mixture of histones (stock solution: 5 mg/ml in H₂O), NAD⁺ (stock solution: 100 mM in H₂O), and [³²P]-NAD⁺ in incubation buffer (50 mM Tris/HCl, pH 8; 0.2 mM DTT; 4 mM MgCl₂) was made. A mixture of the PARP-1 enzyme (5-10 μg/ml) and nicked DNA was also made. The nicked DNA was prepared as described in the in vitro SPA for PARP-1 inhibitory activity. Seventy-five μl of the PARP-1 enzyme/DNA mixture together with 1 μl of compound in DMSO and 25 μl of histones-NAD⁺/[³²P]-NAD⁺ mixture was added per well of a 96-well filterplate (0.45 μm, supplier Millipore). The final concentrations in the incubation mixture were 2 μg/ml for the histones, 0.1 mM for the NAD⁺, 200 μM (0.5 μC) for the [3²P]-NAD⁺ and 2 μg/ml for the nicked DNA. Plates were incubated for 15 min. at room temperature and the reaction was terminated by the addition of 10 μl ice cold 100% TCA followed by the addition of 10 μl ice-cold BSA solution (1% in H₂O). The protein fraction was allowed to precipitate for 10 min. at 4° C. and plates were vacuum filtered. The plates were subsequently washed with, for each well, 1 ml of 10% ice cold TCA, 1 ml of 5% ice cold TCA and 1 ml of 5% TCA at room temperature. Finally 100 μl of scintillation solution (Microscint 40, Packard) was added to each well and the plates were transferred to a TopCountNXT™ (supplier: Packard) for scintillation counting and values were expressed as counts per minute (cpm). For each experiment, controls (containing PARP-1 enzyme and DMSO without compound), a blank incubation (containing DMSO but no PARP-1 enzyme or compound) and samples (containing PARP-1 enzyme and compound dissolved in DMSO) were run in parallel. All compounds tested were dissolved and eventually further diluted in DMSO. In first instance, compounds were tested at a concentration of 10⁻⁵M. When the compounds showed activity at 10⁻⁵M, a dose-response curve was made wherein the compounds were tested at concentrations between 10⁻⁵M and 10⁻⁸M. In each test, the blank value was subtracted from both the control and the sample values. The control sample represented maximal PARP-1 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the controls. When appropriate, IC₅₀-values (concentration of the drug, needed to reduce the PARP-1 enzyme activity to 50% of the control) were computed using linear interpolation between the experimental points just above and below the 50% level. Herein the effects of test compounds are expressed as pIC₅₀ (the negative log value of the IC₅₀-value). As a reference compound, 4-amino-1,8-naphthalimide was included to validate the filtration assay. The tested compounds showed inhibitory activity at the initial test concentration of 10⁻⁵M (see Table-2).

In Vitro Scintillation Proximity Assay (SPA) for Tank-2 Inhibitory Activity

Compounds of the present invention were tested in an in vitro assay based on SPA technology with Ni Flash plates (96 or 384 well).

In principle, the assay relies upon SPA technology for the detection of auto-poly(ADP-ribosylation of TANK-2 protein using [3H]-nicotinamide adenine dinucleotide ([3H]-NAD⁺) as ADP-ribosyl donor.

A stock solution of [³H]-NAD⁺/NAD was made by adding 64.6 μl of [³H]-NAD⁺ (0.1 mCi/ml, supplier: Perkin Elmer) and 46.7 μl NAD-stock (10.7 mM, stored at −20° C., supplier Roche) to 1888.7 μl assay buffer (60 mM Tris/HCl, pH 7.4; 0.9 mM DTT; 6 mM MgCl₂). The TANK-2 enzyme was produced as described in EP1238063.60 μl of assay buffer, together with 1 μl of compound in DMSO, 20 μl of [³H]-NAD^(+/)NAD and 20 μl of TANK-2 enzyme (final concentration 6 μg/ml) was added per well into a 96-well Ni-coated flash plate (Perkin Elmer). After incubation of the mixture for 120 min. at room temperature, the reaction was terminated by adding 60 μl of stopsolution (42.6 mg NAD in 6 ml H₂O). The plates were covered with a plate sealer and placed in a TopCountNXT™ (Packard) for scintillation counting. Values were expressed as counts per minute (cpm). For each experiment, controls (containing TANK-2 enzyme and DMSO without compound), a blank incubation (containing DMSO but no TANK-2 enzyme or compound) and samples (containing TANK-2 enzyme and compound dissolved in DMSO) were run in parallel. All compounds tested were dissolved and eventually further diluted in DMSO. In first instance, compounds were tested at a concentration of 10⁻⁵ M. When the compounds showed activity at 10⁻⁵ M, a dose-response curve was made wherein the compounds were tested at concentrations between 10⁻⁵M and 10⁻⁸M. In each test, the blank value was subtracted from both the control and the sample values. The control sample represented maximal TANK-2 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the controls. When appropriate, IC₅₀-values (concentration of the drug, needed to reduce the TANK-2 enzyme activity to 50% of the control) were computed using linear interpolation between the experimental points just above and below the 50% level. Herein the effects of test compounds are expressed as pIC₅₀ (the negative log value of the IC₅₀-value). As reference compounds, 3-aminobenzamide and 4-amino-1,8-naphthalimide were included to validate the SPA assay. Herein the assay was described using 96-well plates. In the assay using 384-well plates the same final concentrations were used and volumes were adapted. If 96-well plate results were available these results were incorporated in Table-2, otherwise the results from the 384-well plate assay were shown.

TABLE 2 in vitro filter in vitro SPA in vitro SPA Compound assay PARP-1 assay PARP-1 assay TANK-2 No pIC50 pIC50 pIC50 1 7.26 6.547 5.074 2 7.764 3 6.69 6.367 5.297 4 7.15 6.601 <5 5 6.569 <5 6 6.71 <5 7 7.051 5.017 8 7.537 <5 9 7.809 <5 10 7.615 <5 11 7.523 7.062 5.671 12 6.726 5.942 5.033 13 7.719 7.122 <5 14 6.116 <5 15 7.45 6.858 <5 16 6.423 <5 19 <5 20 <5 24 6.411 6.012 5.36 25 6.62 5.525 <5 26 7.761 <5 27 6.668 6.067 <5 28 7.343 29 6.52 5.749 <5 30 6.638 6.355 5.398 31 6.926 <5 32 6.963 5.034 33 6.813 <5 34 7.306 6.922 <5 35 6.751 <5 36 7.077 5.504 37 7.209 <5 38 6.83 <5 39 6.672 <5 40 6.664 <5 41 7.424 <5 42 6.748 <5 43 7.246 <5 44 6.656 5.949 <5 45 6.961 5.265 46 6.874 6.074 <5 47 6.741 5.196 48 6.789 5.513 <5 49 6.287 5.418 5.806 50 6.192 5.601 <5 51 6.523 6.365 <5 52 6.448 6.362 5.184 53 6.664 5.972 <5 54 7.037 55 6.677 5.782 5.825 56 6.111 5.249 <5 57 6.326 5.705 5.294 58 6.501 5 5.045 59 6.09 5.482 <5 61 6.528 5.888 <5 62 7.413 63 6.837 6.165 <5 64 7.535 65 7.04 6.07 <5 66 7.016 6.115 5.364 67 6.633 6.519 <5 68 7.301 6.563 <5 69 6.902 5.667 5.258 70 6.572 5.464 5.428 71 6.273 5.13 <5 72 5.979 5.047 <5 73 6.288 5.721 <5 74 6.215 5.493 5.329 75 6.443 5.373 <5 76 6.384 5.44 <5 77 6.774 5.88 5.054 79 <5 80 <5 81 5.555 84 <5

The compounds can be further evaluated in a cellular chemo- and/or radiosensitization assay, an assay measuring inhibition of endogenous PARP-1 activity in cancer cell lines and eventually in an in vivo radiosensitization test. 

1. A compound of formula (I),

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein the dotted line represents an optional bond; n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and when Q is —CR³— the dotted line represents a bond; each X is independently —N< or —CH<; and when X is —CH< then Y is —N<, or —NH—; each Y is independently —N<, —NH—, —CH< or —CH₂—; except when X is —CH< then Y is —N<, or —NH—; L¹ is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; L² is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or —C₁₋₆alkanediyl-substituted with one substituent selected from hydroxy or aryl; R¹ is hydrogen, nitro, halo or amino; R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge; Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino, cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or a ring system selected from

wherein R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl; aryl is phenyl, or phenyl substituted with one or two substituents each independently selected from halo, C₁₋₆alkyl or C₁₋₆alkyloxy; with the proviso that when Q is —C(═O)— and X is —N< and Y is —CH< or —CH₂— and L¹ is a direct bond and L² is a direct bond, or the bivalent radical —C₁₋₆alkanediyl- or —C₁₋₆alkanediyl-substituted with hydroxy and R¹ is hydrogen and R² is hydrogen or C₁₋₆alkyl then Z is other than hydrogen, hydroxy or C₁₋₆alkyl; and when n is 1 and X is —N< and Y is —N< and L¹ and L² are a direct bond and R¹ and R² are hydrogen and Q is —CR³— wherein R³ is chloro then Z is other than the ringsystem (a-3).
 2. A compound as claimed in claim 1 wherein n is 1 or 2; Q is —C(═O)—; Y is —N<, —NH— or —CH<; L¹ is a direct bond or the bivalent radical —NH—; L² is a direct bond or a bivalent radical selected from carbonyl, —C₁₋₆alkanediyl- or —C₁₋₆alkanediyl-substituted with hydroxy; R¹ is hydrogen; R² is hydrogen, arylC₁₋₆alkyl; Z is hydrogen, C₁₋₆alkyloxy, aryloxy, amino, or a ring system selected from (a-2) or (a-3); and R⁴ and R⁵ are each independently selected from hydrogen or halo.
 3. A compound selected from the group consisting of:


4. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein the dotted line represents an optional bond; n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and when Q is —CR³— the dotted line represents a bond; each X is independently —N< or —CH<; and when X is —CH< then Y is —N<, or —NH—; each Y is independently —N<, —NH—, —CH< or —CH₂—; except when X is —CH< then Y is —N<, or —NH—; L¹ is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; L² is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or —C₁₋₆alkanediyl-substituted with one substituent selected from hydroxy or aryl; R¹ is hydrogen, nitro, halo or amino; R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; y (CH₂). the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge; Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino, cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or a ring system selected from

wherein R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl; aryl is phenyl, or phenyl substituted with one or two substituents each independently selected from halo, C₁₋₆alkyl or C₁₋₆alkyloxy; with the proviso that when n is 1 and X is —N< and Y is —N< and L¹ and L² are a direct bond and R¹ and R² are hydrogen and Q is —CR³— wherein R³ is chloro then Z is other than the ringsystem (a-3).
 5. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim
 2. 6. (canceled)
 7. A method of treating a PARP mediated disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, a compound of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein the dotted line represents an optional bond; n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and when Q is —CR³— the dotted line represents a bond; each X is independently —N< or —CH<; and when X is —CH< then Y is —N<, or —NH—; each Y is independently —N<, —NH—, —CH< or —CH₂—; except when X is —CH< then Y is —N<, or —NH—; L¹ is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; L² is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or —C₁₋₆alkanediyl-substituted with one substituent selected from hydroxy or aryl; R¹ is hydrogen, nitro, halo or amino; R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge; Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino, cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or a ring system selected from

wherein R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl; and aryl is phenyl, or phenyl substituted with one or two substituents each independently selected from halo, C₁₋₆alkyl or C₁₋₆alkyloxy.
 8. The method of claim 7, wherein the PARP mediated disorder is a PARP-1 mediated disorder.
 9. The method of claim 7 wherein the treatment involves chemosensitization.
 10. The method of claim 7 wherein the treatment involves radiosensitization.
 11. A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein the dotted line represents an optional bond; n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended; Q is —C(═O)— or —CR³— wherein R³ is halo or C₁₋₆alkyl; and when Q is —CR³— the dotted line represents a bond; each X is independently —N< or —CH<; and when X is —CH< then Y is —N<, or —NH—; each Y is independently —N<, —NH—, —CH< or —CH₂—; except when X is —CH< then Y is —N<, or —NH—; L¹ is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-NH—, —NH— or —NH—C₁₋₆alkanediyl-NH—; L² is a direct bond or a bivalent radical selected from —C₁₋₆alkanediyl-, —C₂₋₆alkenediyl-, carbonyl or —C₁₋₆alkanediyl-substituted with one substituent selected from hydroxy or aryl; R¹ is hydrogen, nitro, halo or amino; R² is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; the central

moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge; Z is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, aryloxy, amino, cyano, arylC₁₋₆alkylamino or benzthiazolyl(C₁₋₆alkyl)amino or a ring system selected from

wherein R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trihalomethyl; and aryl is phenyl, or phenyl substituted with one or two substituents each independently selected from halo, C₁₋₆alkyl or C₁₋₆alkyloxy.
 12. A process for preparing a compound as claimed in claim 1, said process comprising: a) reacting an intermediate of formula (II) with hydrazine, with the formation of a compound of formula (I-a)

b) reacting an intermediate of formula (V), wherein t is an integer with value 0, 1, 2, 3 or 4, with a compound of formula (I-c)

c) reductively N-alkylating the compound of formula (I-c), wherein r is an integer with value 0, 1, 2, 3, 4 or 5 with an appropriate carbonyl intermediate of formula (VIII)

d) preparing the compounds of formula (I-c) (e.g.), or of compounds of formula I, wherein L² is a direct bond or the bivalent radical —C₁₋₆alkanediyl- and Z is amino, starting from compounds of formula (I-e) wherein Z-L²- is arylC₁₋₆alkyl (e.g.) or arylC₁₋₆alkylamino

e) converting compounds of formula (I-j) into the compounds of formula (I-i)

f) deacylating the compounds of formula (I-f) with the formation of compounds with formula (I-c)

g) converting the compounds of formula (I-h) into the compounds of formula (I-g)

h) reacting a compound of formula (I-c), with an intermediate of formula (XI), wherein W is an appropriate leaving group, with the formation of compounds of formula (I-k) or;

and i) reacting an intermediate of formula (IX), with an intermediate of formula (X) with the formation of a compound of formula (I-l).


13. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim
 3. 14. A method of treating a PARP mediated disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim
 2. 15. A method of treating a PARP mediated disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim
 3. 16. A method of treating a PARP mediated disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim
 4. 17. The method of claim 14, wherein the PARP mediated disorder is a PARP-1 mediated disorder.
 18. The method of claim 15 wherein the PARP mediated disorder is a PARP-1 mediated disorder.
 19. The method of claim 16 wherein the PARP mediated disorder is a PARP-1 mediated disorder.
 20. The method of claim 14, wherein the treatment involves chemosensitization.
 21. The method of claim 16, wherein the treatment involves chemosensitization. 